Shared on01 May 25
Fair value Increased 6.82%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 9.02%

AnalystConsensusTarget has decreased revenue growth from 43.3% to 29.3%, increased future PE multiple from 100.5x to 127.6x and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on26 Mar 25
Fair value Increased 2.87%

Future Drug Approvals Will Expand Retinal Disease Treatments

Shared on01 May 25Fair value Increased 6.82%

Shared on24 Apr 25

Shared on17 Apr 25

Shared on09 Apr 25Fair value Increased 0.25%

Shared on02 Apr 25Fair value Decreased 9.02%

Shared on26 Mar 25Fair value Increased 2.87%

Shared on01 May 25
Fair value Increased 6.82%

Shared on09 Apr 25
Fair value Increased 0.25%

Shared on02 Apr 25
Fair value Decreased 9.02%

Shared on26 Mar 25
Fair value Increased 2.87%